NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.343) was uploaded to the NHS England Website on Monday 20, January 2025.
The following changes have been introduced:
Durvalumab in combination with etoposide plus either carboplatin or cisplatin (DUR4)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding; 7 drugs/indications with updated treatment criteria
Abemaciclib (in combination with an aromatase inhibitor) (ABEM1)
The treatment of previously untreated, hormone receptor-positive, HER2- negative, locally advanced or metastatic breast cancer where the following criteria have been met
Treatment criteria (#3 and 10) updated
Abemaciclib (in combination with fulvestrant) (ABEM2)
The treatment of hormone receptor- positive, HER2-negative, locally advanced or metastatic breast cancer where the following criteria have been met
Treatment criteria (#7 and 12) updated
Atezolizumab in combination with carboplatin and etoposide (ATE7)
For the first-line treatment of adult patients with extensive-stage small cell lung cancer where the following criteria have been met
Treatment criteria (#2, 11 and 13) updated
Palbociclib (in combination with an aromatase inhibitor) (PAL1)
The treatment of previously untreated, hormone receptor-positive, HER2- negative, locally advanced or metastatic breast cancer
Treatment criteria (#3 and 10) updated
Palbociclib in combination with fulvestrant (PAL2)
For hormone receptor-positive, HER2- negative, locally advanced or metastatic breast cancer where the following criteria are met:
Treatment criteria (#7 and 12) updated
Ribociclib (in combination with an aromatase inhibitor) (RIB1)
The treatment of previously untreated, hormone receptor-positive, HER2- negative, locally advanced or metastatic breast cancer
Treatment criteria (#3 and 10) updated
Ribociclib in combination with fulvestrant (RIB2)
The treatment of hormone receptor- positive, HER2-negative, locally advanced or metastatic breast cancer where the following criteria have been met
Treatment criteria (#7 and 12) updated